Related Experiment Video
Updated: May 17, 2025

09:51
Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
Published on: June 30, 2023
720
Targeting Autophagy for Pituitary Tumors
Evan Yin1, Motoyasu Satou2, Toru Tateno1
1Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada.
Cancers
|May 14, 2025
Summary
Autophagy, a cellular recycling process, plays a complex role in pituitary tumors. Targeting autophagy presents a potential therapeutic strategy for these tumors, requiring further research.
Area of Science:
- Endocrinology
- Cell Biology
- Oncology
Background:
- Pituitary tumors are classified as functioning or non-functioning based on hormone production.
- Impaired autophagy, a cellular recycling mechanism, is linked to pituitary tumorigenesis and hormone dysregulation.
Purpose of the Study:
- To comprehensively review the relationship between autophagy and pituitary tumors.
- To explore autophagy's dual role in cancer and its specific mechanisms (macroautophagy, mitophagy, crinophagy) in pituitary tumorigenesis.
- To analyze therapeutic interventions targeting autophagy in pituitary tumor cells.
Main Methods:
- Literature review of studies on autophagy and pituitary tumors.
- Analysis of autophagy's role in cancer, pituitary tumorigenesis, and hormone regulation.
- Examination of therapeutic strategies involving autophagy modulation.
Main Results:
- Autophagy has a context-dependent dual role in cancer, acting as both a tumor suppressor and promoter.
- Specific autophagy mechanisms are relevant to pituitary tumor development and hormone regulation.
- Therapeutic interventions modulating autophagy show potential but require careful consideration due to complexity.
Conclusions:
- Targeting autophagy is a promising therapeutic avenue for pituitary tumors.
- Challenges exist in interpreting autophagy activity and its interaction with hormone production.
- Further research and clinical trials are essential to optimize autophagy-targeted therapies for individual patients.
Related Concept Videos
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K

